Literature DB >> 11698342

Cyclin D1 (CCND1) genotype is associated with tumour grade in sporadic pituitary adenomas.

D J Simpson1, A A Fryer, A B Grossman, J A Wass, M Pfeifer, J M Kros, R N Clayton, W E Farrell.   

Abstract

The cyclin D1 (CCND1) gene contains a frequent A/G polymorphism within the splice donor region of exon 4/intron 4. CCND1 genotype is associated with clinical outcome in a number of malignancies although prognostic significance varies with tumour type. We examined CCND1 allele frequencies and genotype distribution in 294 patients with sporadic pituitary adenomas of various histologies. CCND1 allele frequencies and distribution of genotypes were similar in the 294 cases compared with previously reported control populations. Analysis according to tumour subtype showed no statistical difference in allele frequencies compared with controls. However, CCND1 genotype distribution in the somatotrophinomas showed a significant difference compared with normal controls (P = 0.008). We next examined CCND1 allele frequencies and genotype distribution across the tumour grades. Within the total tumour cohort the CCND1 allele frequencies showed a significant inverse relationship across the tumour grades (P = 0.005). The CCND1 A allele progressively increased from grade 1 (0.37) through to grade 4 (0.62) tumours, whilst the CCND1 G allele frequency progressively decreased from grade 1 (0.63) through to grade 4 (0.38) tumours. Trend analysis of CCND1 genotypes showed a significant progressive increase in AA frequency from grade 1 (15%) through to grade 4 (46%) tumours (P = 0.005). The CCND1 GG genotype progressively decreased from grade 1 (41%) through to grade 4 (23%) tumours (P = 0.204). No statistical significance was observed between CCND1 AG genotype and tumour grades. While the functional significance of the observed segregation of the CCND1 A/G polymorphism and tumour grade is unclear, our data suggest that CCND1 allele frequencies and genotype distributions show significant differences between tumour grades in sporadic pituitary adenomas. Since CCND1 genotype may be determined by analysis of peripheral blood samples it may provide a useful predictive marker for those tumours likely to show invasive behaviour. This may be clinically useful in indicating which tumours should receive adjunctive treatment (e.g. radiotherapy) immediately after surgical resection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698342     DOI: 10.1093/carcin/22.11.1801

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  12 in total

1.  Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population.

Authors:  Xuwei Hou; Sili Wang; Yuling Zhou; Ziliang Xu; Yao Zou; Xiaofan Zhu; Mingzhe Han; Tianxiang Pang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

2.  Stable knockdown of LRG1 by RNA interference inhibits growth and promotes apoptosis of glioblastoma cells in vitro and in vivo.

Authors:  Di Zhong; Siren Zhao; Guangxu He; Jinku Li; Yanbin Lang; Wei Ye; Yongli Li; Chuanlu Jiang; Xianfeng Li
Journal:  Tumour Biol       Date:  2015-01-15

3.  Cyclin D1 genotype and expression in sporadic hemangioblastomas.

Authors:  Johanna M M Gijtenbeek; Sandra H E Boots-Sprenger; Barbara Franke; Pieter Wesseling; Judith W M Jeuken
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

4.  Association between cyclin D1 polymorphism with CpG island promoter methylation status of tumor suppressor genes in gastric cancer.

Authors:  Tomomitsu Tahara; Tomoyuki Shibata; Masakatsu Nakamura; Hiromi Yamashita; Daisuke Yoshioka; Masaaki Okubo; Joh Yonemura; Yoshiteru Maeda; Naoko Maruyama; Toshiaki Kamano; Yoshio Kamiya; Hiroshi Fujita; Yoshihito Nakagawa; Mitsuo Nagasaka; Masami Iwata; Ichiro Hirata; Tomiyasu Arisawa
Journal:  Dig Dis Sci       Date:  2010-04-16       Impact factor: 3.199

Review 5.  Best Practice No 172: pituitary gland pathology.

Authors:  J W Ironside
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

6.  Association between p16(CDKN2A) C540G polymorphism and tumor behavior in prolactinoma: A single-center study.

Authors:  Soner Cander; Mutlu Karkucak; Ozen Oz Gul; Sebnem Ozemri Sag; Tahsin Yakut; Canan Ersoy; Ercan Tuncel; Erdinc Erturk
Journal:  Biomed Rep       Date:  2014-05-19

7.  shRNA-Mediated Silencing of Y-Box Binding Protein-1 (YB-1) Suppresses Growth of Neuroblastoma Cell SH-SY5Y In Vitro and In Vivo.

Authors:  Hong Wang; Ruowen Sun; Min Gu; Shuang Li; Bin Zhang; Zuofei Chi; Liangchun Hao
Journal:  PLoS One       Date:  2015-05-19       Impact factor: 3.240

8.  CCND1 gene polymorphic variants in patients with differentiated thyroid carcinoma.

Authors:  Szymon Hryhorowicz; Katarzyna Ziemnicka; Marta Kaczmarek-Ryś; Justyna Hoppe-Gołębiewska; Andrzej Pławski; Marzena Skrzypczak-Zielińska; Małgorzata Szkudlarek; Monika Gołąb; Bartłomiej Budny; Marek Ruchała; Ryszard Słomski
Journal:  Oncol Lett       Date:  2014-10-15       Impact factor: 2.967

9.  LRG1 promotes proliferation and inhibits apoptosis in colorectal cancer cells via RUNX1 activation.

Authors:  Ying Zhou; Xintian Zhang; Jingjing Zhang; Jingyuan Fang; Zhizheng Ge; Xiaobo Li
Journal:  PLoS One       Date:  2017-04-04       Impact factor: 3.240

10.  Overexpression of MYCT1 Inhibits Proliferation and Induces Apoptosis in Human Acute Myeloid Leukemia HL-60 and KG-1a Cells in vitro and in vivo.

Authors:  Shuang Fu; Yu Fu; Fang Chen; Yanping Hu; Bi Quan; Jihong Zhang
Journal:  Front Pharmacol       Date:  2018-09-18       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.